CA3056249A1 - Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas - Google Patents

Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas Download PDF

Info

Publication number
CA3056249A1
CA3056249A1 CA3056249A CA3056249A CA3056249A1 CA 3056249 A1 CA3056249 A1 CA 3056249A1 CA 3056249 A CA3056249 A CA 3056249A CA 3056249 A CA3056249 A CA 3056249A CA 3056249 A1 CA3056249 A1 CA 3056249A1
Authority
CA
Canada
Prior art keywords
cell
linker
cells
anchor
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3056249A
Other languages
English (en)
French (fr)
Inventor
Scott K. Dessain
Rama Devudu Puligedda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lankenau Institute for Medical Research
Original Assignee
Lankenau Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lankenau Institute for Medical Research filed Critical Lankenau Institute for Medical Research
Publication of CA3056249A1 publication Critical patent/CA3056249A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3056249A 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas Pending CA3056249A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762476599P 2017-03-24 2017-03-24
US62/476,599 2017-03-24
US201762526608P 2017-06-29 2017-06-29
US62/526,608 2017-06-29
PCT/US2018/024073 WO2018175917A1 (en) 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Publications (1)

Publication Number Publication Date
CA3056249A1 true CA3056249A1 (en) 2018-09-27

Family

ID=63584730

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3056249A Pending CA3056249A1 (en) 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Country Status (7)

Country Link
US (2) US11946074B2 (https=)
EP (1) EP3601558A4 (https=)
JP (1) JP7287940B2 (https=)
CA (1) CA3056249A1 (https=)
IL (2) IL312457A (https=)
SG (2) SG11201908384XA (https=)
WO (1) WO2018175917A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201908384XA (en) * 2017-03-24 2019-10-30 Lankenau Inst Medical Res Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
WO2020171020A1 (ja) * 2019-02-18 2020-08-27 株式会社エヌビィー健康研究所 細胞の選抜方法、核酸の製造方法、組換え細胞の製造方法、目的物質の製造方法、医薬組成物の製造方法、及び試薬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376170B1 (en) * 1994-10-03 2002-04-23 The Scripps Research Institute Ligand capture-directed selection of antibody
DE19900635A1 (de) * 1999-01-11 2000-07-13 Deutsches Krebsforsch Selektion von monoklonalen Antikörpern
WO2002057423A2 (en) * 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) * 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
JP2004525627A (ja) 2001-02-20 2004-08-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド モノクローナル抗体の迅速な産生
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
WO2009131605A2 (en) 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
US8067339B2 (en) * 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
US20110275535A1 (en) 2008-12-16 2011-11-10 Novartis Ag Yeast Display Systems
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
EP2390661B1 (en) * 2010-05-02 2015-06-24 Miltenyi Biotec GmbH An anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell
TW202423993A (zh) 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI619727B (zh) 2013-02-27 2018-04-01 中央研究院 抗體之原位親和力成熟作用
TWI588259B (zh) * 2015-03-06 2017-06-21 Methods for screening antigen-specific fusion tumor cells
SG11201908384XA (en) * 2017-03-24 2019-10-30 Lankenau Inst Medical Res Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Also Published As

Publication number Publication date
IL269472B2 (en) 2024-10-01
SG10202110530WA (en) 2021-11-29
IL312457A (en) 2024-06-01
WO2018175917A1 (en) 2018-09-27
US11946074B2 (en) 2024-04-02
EP3601558A1 (en) 2020-02-05
US20240191207A1 (en) 2024-06-13
US20200010810A1 (en) 2020-01-09
SG11201908384XA (en) 2019-10-30
EP3601558A4 (en) 2021-01-06
JP2020515288A (ja) 2020-05-28
IL269472B1 (en) 2024-06-01
JP7287940B2 (ja) 2023-06-06
IL269472A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
Wellner et al. Rapid generation of potent antibodies by autonomous hypermutation in yeast
US20240191207A1 (en) Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
Yu et al. Single domain antibody: Development and application in biotechnology and biopharma
JP2019094336A (ja) 試料に関連するポリヌクレオチドの同定
JP7022067B2 (ja) Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
JP6118345B2 (ja) 抗ホスホリパーゼｄ４抗体
Fabra-García et al. Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes
EA019505B1 (ru) Способ получения иммортализованных клеток, секретирующих антитела, популяция иммортализованных клеток и ее применения
CN116640216B (zh) 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用
CN120842435A (zh) 抗hk2嵌合抗原受体(car)
Kivi et al. HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species
CN110382548A (zh) 选择抗体的方法
Seydoux et al. Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
Yu et al. Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2
JP2022514423A (ja) 生物学的結合分子の選別方法
Abba Moussa et al. Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches
Challa et al. Function-first discovery of high affinity monoclonal antibodies using Nanovial-based plasma B cell screening
Ren et al. RAMIHM generates fully human monoclonal antibodies by rapid mRNA immunization of humanized mice and BCR-seq
Chai et al. A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain
CN111876476A (zh) 用于扩增马抗体的巢式pcr引物、试剂盒及其应用
Marsman et al. Immune counter-evolution: immortalized B cell clones can undergo ex vivo directed evolution to counteract viral escape
JP7561405B2 (ja) 抗体において自己抗原に対する反応性を低減する方法、および低減された自己抗原に対する反応性を有する抗体
Dai et al. Off-target reactivity in clinical monoclonal antibodies
Wang et al. Development and characterization of a mouse-panda chimeric antibody with neutralizing activity against canine distemper virus
Gu et al. Specific human antibodies against SARS-CoV-2 and monkeypox virus generated via a rapid construction and screening system

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220915

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250313

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250313

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250617

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251017